As more practices adopt the COME HOME model, they are adapting it to fit their needs, explained Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants. However, some practices may not have the resources to keep up with data collection requirements while ramping up clinical interventions.
As more practices adopt the COME HOME model, they are adapting it to fit their needs, explained Barbara McAneny, MD, chief medical officer of New Mexico Oncology Hematology Consultants. However, some practices may not have the resources to keep up with data collection requirements while ramping up clinical interventions.
Transcript (slightly modified)
How has the COME HOME model changed over the years?
At the beginning of COME HOME, it was 7 practices across the country. My practice, New Mexico Cancer Center, had done a lot of these policies and procedures because I take care of poor people, and having them be able to afford cancer care was obviously very important. As we moved it to the other practices, it had to adapt a little bit to work in each individual market. Some of the practices just did their Medicare patients; some like New Mexico Cancer Center expanded and did these processes for all of our patients.
It has changed a bit when it turned into the Oncology Care Model. The data collection requirements and the idea of superimposing the risk structure, this payment structure, on top of it is very different. When we did COME HOME, we added up all the costs of paying nurses to sit on the phone talking to patients as part of the triage pathway, the extra time it takes to have nurses and others educating patients as to how their disease would work and how to use our system to keep themselves healthy, and be able to have the opportunity costs of having expanded hours and having the ability to see patients the day they need to be seen.
When we added up all those costs, it came out more than the $160 per month that is the MEOS [Monthly Enhanced Oncology Services] payment, so I’m concerned that as it goes towards Medicare that practices will not have sufficient resources to really ramp up the clinical interventions that they need in their practices to really make it work. I also think that there’s a risk, like there was with the accountable care organizations, that all of the money paid in the MEOS payment will go towards the data collection to give back to Medicare, and that’s not really the intent.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More